Russia’s COVID-19 Defense May Depend on Mystery Vaccine from Former Bioweapons Lab–But Does It Work?

April 6, 2021

(Science) – But only in late March did VECTOR publish any clinical data on EpiVacCorona, which consists mainly of multiple protein bits, or peptides, from the pandemic coronavirus. The paper, in an obscure Russian journal, described safety tests in 14 people, and a phase 2, placebo-controlled trial in 86 people. The authors reported no safety issues and said volunteers who received vaccine produced antibodies that block SARS-CoV-2’s infectivity. But VECTOR has not reported evidence that the vaccine actually protects people from COVID-19.